Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8RYM

Structure of S2 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide

Summary for 8RYM
Entry DOI10.2210/pdb8rym/pdb
DescriptorHLA class I histocompatibility antigen, A alpha chain, Beta-2-microglobulin, ELFSYLIEK peptide, ... (6 entities in total)
Functional Keywordstcr, hla, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains5
Total formula weight93980.35
Authors
Karuppiah, V. (deposition date: 2024-02-09, release date: 2024-09-04, Last modification date: 2025-02-12)
Primary citationKaruppiah, V.,Sangani, D.,Whaley, L.,Pengelly, R.,Uluocak, P.,Carreira, R.J.,Hock, M.,Cristina, P.D.,Bartasun, P.,Dobrinic, P.,Smith, N.,Barnbrook, K.,Robinson, R.A.,Harper, S.
Broadening alloselectivity of T cell receptors by structure guided engineering.
Sci Rep, 14:26851-26851, 2024
Cited by
PubMed Abstract: Specificity of a T cell receptor (TCR) is determined by the combination of its interactions to the peptide and human leukocyte antigen (HLA). TCR-based therapeutic molecules have to date targeted a single peptide in the context of a single HLA allele. Some peptides are presented on multiple HLA alleles, and by engineering TCRs for specific recognition of more than one allele, there is potential to expand the targetable patient population. Here, as a proof of concept, we studied two TCRs, S2 and S8, binding to the PRAME peptide antigen (ELFSYLIEK) presented by HLA alleles HLA-A*03:01 and HLA-A*11:01. By structure-guided affinity maturation targeting a specific residue on the HLA surface, we show that the affinity of the TCR can be modulated for different alleles. Using a combination of affinity maturation and functional T cell assay, we demonstrate that an engineered TCR can target the same peptide on two different HLA alleles with similar affinity and potency. This work highlights the importance of engineering alloselectivity for designing TCR based therapeutics suitable for differing global populations.
PubMed: 39500929
DOI: 10.1038/s41598-024-75140-7
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.34 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon